Skip To Main Content
Michal Chovanec on Muck Rack

Michal Chovanec

As seen in: Nature, Educational Studies, MDPI, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michal

Contact Michal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early systemic inflammatory–metabolic trajectory phenotypes are associated with survival outcomes in metastatic renal cell carcinoma treated with nivolumab

|
By Ondrej Fiala, Tomas Buchler, Alexandr Poprach, Jindřich Kopecký, Jana Obertová, Martina Spisarová, Michaela Tkadlecová, Peter Priester, Monika Zak, Michal Chovanec, Bohuslav Melichar, Patrik Palacka, Radka Lohynská, Lucie Grmelová, Katarína Rejleková, Petr Stránský Jr
| Nature Verified
Abstract Prognosis in metastatic renal cell carcinoma (mRCC) treated with PD-1 blockade remains difficult to estimate early during therapy. Routine laboratory markers of systemic inflammation and metabolic stress are widely available, yet single-marker approaches may not reflect coordinated early inflammatory–metabolic dynamics. In a multicenter real-world cohort of previously treated mRCC patients receiving nivolumab monotherapy, we applied a prespecified day-28 (1-month) landmark framework.
Open in Who Shared Issue with article?

Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab

|
By Michal Chovanec, Monika Zak, Jana Obertová, Alexander Savka
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database - British Journal of Cancer

|
By Jakob Lauritsen, Di Jiang, Robert Huddart, Michal Chovanec, Christian D Fankhauser, Axel Heidenreich, Joerg Beyer
| Nature Verified
Abstract Active surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate. In the IGCCCG Update database, we compared the outcomes of gonadal disseminated GCT relapsing from initial CSI to outcomes of patients with de novo metastatic GCT.
Open in Who Shared Issue with article?
See all 10 articles